Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Natera's Signatera MRD test was named to TIME's Best Inventions of 2026 list in the Medical & Healthcare category. Natera was also named to Fortune's Future 120 list in October 2026, highlighting companies poised to define the next chapter of business and innovation. Signatera remains the most widely adopted and extensively validated MRD test, supported by more than 200 peer-reviewed publications and used by more than 55% of U.S.
Key figures
- Oncologist adoption us
- 55%
- Peer reviewed publications signatera
- 200
- Peer reviewed publications company wide
- 400
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.